Tirzepatide vs Semaglutide: Comparing the Two Leading GLP-1 Weight Loss Medications

Table of Contents

Tirzepatide vs Semaglutide: Quick Comparison

Choosing between tirzepatide and semaglutide is one of the most common questions we hear from members exploring GLP-1 weight loss medications. Both are FDA-approved, evidence-backed options that deliver meaningful results when combined with lifestyle changes. But they work differently, and those differences matter.

Here is a side-by-side overview to help you compare the two medications at a glance.

Feature	Tirzepatide (Mounjaro/Zepbound)	Semaglutide (Ozempic/Wegovy)
Mechanism	Dual GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
Weight Loss Brand	Zepbound	Wegovy
Diabetes Brand	Mounjaro	Ozempic
Avg. Weight Loss	20.2% of body weight (SURMOUNT-5)	13.7% of body weight (SURMOUNT-5)
FDA Weight Loss Approval	2023	2021
Injection Frequency	Once weekly	Once weekly
Manufacturer	Eli Lilly	Novo Nordisk

How Semaglutide Works

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a natural gut hormone your body produces after eating that signals your brain to reduce appetite, slows gastric emptying so you feel full longer, and helps regulate blood sugar by stimulating insulin release.

By activating GLP-1 receptors in the brain’s appetite centers, semaglutide reduces hunger and food cravings, leading to a significant decrease in caloric intake. The medication also slows the rate at which food leaves your stomach, which contributes to prolonged satiety after meals.

Semaglutide is available under two brand names. Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related health condition. In 2024, semaglutide also received an expanded indication for reducing major adverse cardiovascular events based on the SELECT trial.

How Tirzepatide Works

Tirzepatide takes a different approach by targeting two hormones instead of one. It is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, making it the first medication in its class to activate both of these incretin pathways simultaneously.

The addition of GIP receptor activation provides benefits beyond what GLP-1 alone offers. GIP enhances the body’s insulin response, supports more efficient fat metabolism, and works synergistically with GLP-1 to amplify appetite suppression. This dual mechanism sends stronger satiety signals to the brain, resulting in reduced hunger and decreased caloric intake.

Tirzepatide is sold under the brand name Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Zepbound received FDA approval in 2023 for adults with obesity or overweight with at least one weight-related comorbidity. Researchers believe the dual-agonist approach helps explain why tirzepatide consistently produces greater weight reduction in clinical trials.

Weight Loss Results: Head-to-Head Clinical Data

Until recently, comparing tirzepatide and semaglutide required looking at separate clinical trial programs. The STEP trials evaluated semaglutide, while the SURMOUNT trials studied tirzepatide. In May 2025, the landmark SURMOUNT-5 trial, published in the New England Journal of Medicine, provided the first direct head-to-head comparison.

STEP Trials (Semaglutide)

The STEP 1 trial enrolled 1,961 adults with obesity or overweight. Participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks when combined with diet and exercise modifications. Approximately 69% of participants achieved at least 10% weight loss, a threshold associated with clinically meaningful health improvements including reduced blood pressure and improved metabolic markers.

SURMOUNT Trials (Tirzepatide)

The SURMOUNT-1 trial included 2,539 participants. Those taking tirzepatide 15 mg weekly lost an average of 20.9% of their body weight over 72 weeks. More than 50% of participants achieved at least 20% weight loss, a result that was unprecedented in pharmaceutical weight management at the time.

SURMOUNT-5: The Direct Comparison

SURMOUNT-5 randomized 751 adults with obesity or overweight (without type 2 diabetes) to receive maximum tolerated doses of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. The results were definitive:

Average weight loss: 20.2% with tirzepatide vs. 13.7% with semaglutide (47% greater relative weight loss)
Absolute weight lost: 50.3 lbs (22.8 kg) with tirzepatide vs. 33.1 lbs (15.0 kg) with semaglutide
Achieved 10% or more weight loss: 81.6% with tirzepatide vs. 60.5% with semaglutide
Achieved 15% or more weight loss: 64.6% with tirzepatide vs. 40.1% with semaglutide
Achieved 25% or more weight loss: 31.6% with tirzepatide vs. 16.1% with semaglutide
Waist circumference reduction: 7.2 inches (18.4 cm) with tirzepatide vs. 5.1 inches (13.0 cm) with semaglutide

Notably, the study also found that women experienced greater weight loss with tirzepatide than men, with an average 23.8% reduction in body weight compared to 18.0% for men. Both medications are highly effective, but the data consistently shows tirzepatide delivers superior weight reduction outcomes.

Side Effect Comparison

Both tirzepatide and semaglutide affect the gastrointestinal system and appetite regulation, which means they share a similar side effect profile. The most common side effects are GI-related and typically mild to moderate in severity, occurring primarily during the initial dose escalation period.

Common Side Effects of Both Medications

Nausea (reported in approximately 44% of participants for both medications in SURMOUNT-5)
Diarrhea
Vomiting
Constipation
Abdominal discomfort
Decreased appetite (an expected therapeutic effect)

In SURMOUNT-5, serious adverse events were reported by 4.8% of tirzepatide patients and 3.5% of semaglutide patients. One confirmed case of pancreatitis occurred in the semaglutide group. Two semaglutide patients discontinued due to gallbladder-related issues (cholelithiasis), while no tirzepatide patients discontinued for this reason.

Most side effects improve within 4 to 8 weeks as the body adjusts to the medication. Gradual dose titration, which both medications require, helps minimize GI symptoms during the adjustment period. Working with a medical provider who can adjust the titration schedule based on your individual tolerance is critical for managing side effects effectively.

Cost and Insurance Coverage Comparison

Cost is a significant factor when choosing between these medications, and the landscape continues to evolve as insurance coverage expands.

Cost Factor	Tirzepatide (Zepbound)	Semaglutide (Wegovy)
List Price (Monthly)	~$1,000-$1,100	~$1,300-$1,400
Insurance Coverage	Growing but varies by plan	More established coverage
Manufacturer Savings	Lilly savings card available	Novo Nordisk savings program
Medicare/Medicaid	Limited; expanding in 2025	Limited; expanding in 2025

Insurance coverage for both medications varies significantly depending on your plan. Some commercial insurance plans cover one but not the other, while others may require prior authorization or step therapy (trying one medication before switching). Manufacturer savings programs can reduce out-of-pocket costs substantially for eligible commercially insured patients.

At 1st Optimal, our Membership Managers help members navigate insurance coverage and identify the most cost-effective path to starting treatment. We work to ensure you have access to the right medication at the best possible price.

Dosing and Administration

Both medications are administered as once-weekly subcutaneous injections and follow a gradual titration schedule to minimize side effects.

Tirzepatide Dosing Schedule

Starting dose: 2.5 mg weekly for 4 weeks
Increase to: 5 mg weekly for 4 weeks
Increase to: 7.5 mg weekly for 4 weeks
Increase to: 10 mg weekly for 4 weeks
Maximum dose: 15 mg weekly (if tolerated and needed)

Semaglutide Dosing Schedule

Starting dose: 0.25 mg weekly for 4 weeks
Increase to: 0.5 mg weekly for 4 weeks
Increase to: 1.0 mg weekly for 4 weeks
Increase to: 1.7 mg weekly for 4 weeks
Maximum dose: 2.4 mg weekly

Both medications use pre-filled pen injection devices that are designed for easy self-administration at home. Your healthcare provider will guide you through the injection technique during your initial consultation. Injections can be given in the abdomen, thigh, or upper arm, and the injection site should be rotated weekly.

Who Should Choose Tirzepatide vs. Semaglutide

Choosing between these medications depends on several individual factors. Here is a practical decision framework to discuss with your healthcare provider:

Tirzepatide may be a better fit if you:

Have a significant amount of weight to lose (BMI 35 or above)
Want to maximize total weight loss potential
Have not responded adequately to GLP-1-only medications
Have metabolic conditions that may benefit from dual-agonist therapy
Are a woman, given the SURMOUNT-5 finding of greater weight loss in female participants

Semaglutide may be a better fit if you:

Have existing cardiovascular disease (semaglutide has proven cardiovascular outcomes data from SELECT)
Prefer a medication with a longer track record and more published clinical data
Have insurance coverage that favors semaglutide
Are looking for a well-established treatment option with broad physician familiarity

The right choice depends on your health history, weight loss goals, insurance situation, and how your body responds to treatment. This is exactly why working with a knowledgeable healthcare provider is essential.

Can You Switch Between Tirzepatide and Semaglutide?

Yes, switching between these medications is possible and relatively common under proper medical supervision. Reasons to consider switching include:

Weight loss plateau: If progress has stalled on one medication, switching to the other may restart weight loss
Side effect management: Some patients tolerate one medication better than the other
Insurance or cost changes: Coverage shifts may make one option more financially accessible
Desire for greater results: Patients on semaglutide may want to try tirzepatide for its potentially greater efficacy

When switching, your provider will typically start the new medication at a lower dose and follow the standard titration schedule, even if you were on a high dose of the previous medication. There is usually a brief washout period between stopping one and starting the other, and your provider will monitor your response closely during the transition.

How 1st Optimal Helps You Choose the Right GLP-1 Medication

At 1st Optimal, we take a data-driven approach to GLP-1 weight loss therapy. Choosing between tirzepatide and semaglutide is not a one-size-fits-all decision, and we believe the best outcomes come from personalized medical evaluation.

Here is how we help our members make the right choice:

Comprehensive lab work: We start with advanced diagnostic testing, including metabolic panels, hormone levels, and other biomarkers, to understand your unique health profile before recommending a medication
Physician-guided selection: Our medical providers evaluate your health history, weight loss goals, existing conditions, and medication tolerance to recommend the GLP-1 medication best suited to you
Dedicated Membership Manager: Every member is paired with a Membership Manager who provides ongoing support, answers questions, and helps coordinate refills, labs, and follow-up appointments
Telehealth convenience: All consultations and follow-ups are conducted virtually, so you can access expert care from anywhere in the United States
Ongoing monitoring: We track your progress with regular lab work and check-ins to adjust your treatment plan as needed for optimal results

Whether you are just starting to explore GLP-1 options or considering a switch, our team is here to guide you. Learn more about our GLP-1 medical weight loss program or book a consultation to get started.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

Based on the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in May 2025, tirzepatide produced 47% greater relative weight loss than semaglutide over 72 weeks (20.2% vs. 13.7% average body weight reduction). However, both medications are highly effective, and semaglutide remains an excellent option, particularly for patients with cardiovascular disease who may benefit from its proven cardiovascular outcomes data.

What are the main side effects of tirzepatide and semaglutide?

Both medications share similar gastrointestinal side effects, including nausea, diarrhea, vomiting, constipation, and decreased appetite. These side effects are typically mild to moderate and improve within 4 to 8 weeks as the body adjusts. Gradual dose titration helps minimize symptoms during the adjustment period.

Can I switch from Ozempic or Wegovy to Mounjaro or Zepbound?

Yes, switching is possible under medical supervision. Your provider will start the new medication at a lower dose and follow the standard titration schedule. Common reasons for switching include weight loss plateaus, side effect management, and insurance or cost considerations.

How much do tirzepatide and semaglutide cost without insurance?

Without insurance, tirzepatide (Zepbound) costs approximately $1,000 to $1,100 per month, while semaglutide (Wegovy) costs approximately $1,300 to $1,400 per month. Both manufacturers offer savings programs for eligible commercially insured patients, and coverage is expanding as more insurance plans include these medications.

How long does it take to see weight loss results?

Most patients begin to notice weight loss within the first 4 to 8 weeks of treatment as they titrate to therapeutic doses. In clinical trials, weight loss continued progressively through 72 weeks of treatment. Maximum results are typically seen after 12 to 18 months of consistent use combined with diet and exercise modifications.

Are tirzepatide and semaglutide safe for long-term use?

Both medications have been studied in clinical trials lasting 68 to 72 weeks with established safety profiles. Common side effects are primarily gastrointestinal and tend to improve over time. Long-term cardiovascular outcomes data exists for semaglutide (SELECT trial), and similar studies are underway for tirzepatide (SURPASS-CVOT). As with any prescription medication, long-term use should be monitored by a qualified healthcare provider.

Do I need a prescription for tirzepatide or semaglutide?

Yes, both tirzepatide and semaglutide are prescription medications that require evaluation by a licensed healthcare provider. At 1st Optimal, our physicians conduct thorough evaluations including lab work to determine if GLP-1 therapy is appropriate for you and which medication best fits your health profile.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual results may vary. The clinical trial data referenced in this article represents average outcomes and may not predict individual results.